Abstract: A vehicle includes a hood at a front end, a frunk under the hood, and a cabin. The vehicle includes a cross-beam positioned between the frunk and the cabin, and configured to inhibit protrusion of the frunk into the cabin in a frontal impact. The vehicle also includes a frame and the cross-beam is coupled to the frame. The cross-beam is a unitary member that is coupled to the frame or the cross-beam includes two members separated by a gap and each member is coupled to the frame. The frame includes shock towers for coupling the cross-beam to the frame. The frame can also include a bracket for coupling the cross beam to the frame.

Abstract: A vehicle includes a hood at a front end, a frunk under the hood, and a cabin. The vehicle includes a cross-beam positioned between the frunk and the cabin, and configured to inhibit protrusion of the frunk into the cabin in a frontal impact. The vehicle also includes a frame and the cross-beam is coupled to the frame. The cross-beam is a unitary member that is coupled to the frame or the cross-beam includes two members separated by a gap and each member is coupled to the frame. The frame includes shock towers for coupling the cross-beam to the frame. The frame can also include a bracket for coupling the cross beam to the frame.

Abstract: The present invention provides an improved synthesis of a class of steroid saponins. Furthermore, the present invention provides a method of selectively discriminating between the C2 and C3 hydroxyl groups of a mono-glycosylated steroid saponin—a key step in the preparation of this class of compounds. Additionally, the present invention provides a range of steroid saponin derivatives, and methods of making them.

Abstract: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.

Abstract: A side curtain air bag system deploys downward during a crash event into a protection zone overlapping an out-of-position head region. An inflator discharges an inflation gas upon the occurrence of the crash event. The system employs an inflatable bag including first, second, and third chambers. The second chamber has a respective deployed position coinciding with the out-of-position head region. The first chamber has a respective deployed position between the B-pillar and the deployed position of the second chamber. The third chamber has a respective deployed position along a lateral edge of the inflatable bag so that the second chamber is disposed between the first and third chambers. The chambers are configured so that the third chamber substantially fills prior to expansion of the second chamber, whereby the inflatable bag substantially completes its downward movement prior to full expansion of the second chamber.

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).

Abstract: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.

Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

Abstract: An inflatable safety curtain for use in a vehicle interior is provided. A first inflatable portion may be mounted to the vehicle interior. A second inflatable portion may be mounted to the first portion. The first and second portions may be in fluid communication. A pressure control device is disposed between the first and second inflatable portions to selectively prevent fluid communication between the first and second portion. The pressure control device is a flexible valve from fabric or a memory shape material, a chamber valve having an enlarged opening, or a flapper valve.

Abstract: A process is disclosed for preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (I), or (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, the compound of formula (Ia) involving, as a key step, the enzyme-catalysed enantioselective hydrolysis of a racemic 3,4-trans-disubstituted pyrrolidinone compound of formula (II).